CLINICAL TRIALS PROFILE FOR RIVASTIGMINE
✉ Email this page to a colleague
All Clinical Trials for rivastigmine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000174 ↗ | Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) | Completed | Novartis | Phase 3 | 1969-12-31 | This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico. Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia. |
| NCT00099216 ↗ | Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia | Completed | Novartis Pharmaceuticals | Phase 3 | 2001-08-01 | The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia. |
| NCT00099242 ↗ | Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease | Completed | Novartis | Phase 3 | 2003-11-01 | The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease. |
| NCT00099242 ↗ | Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease | Completed | Novartis Pharmaceuticals | Phase 3 | 2003-11-01 | The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease. |
| NCT00102284 ↗ | Neuromodulation and Language Acquisition (Project Stage Ia) | Terminated | University Hospital Muenster | Phase 4 | 2004-03-01 | The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for rivastigmine
Condition Name
Clinical Trial Locations for rivastigmine
Trials by Country
Clinical Trial Progress for rivastigmine
Clinical Trial Phase
Clinical Trial Sponsors for rivastigmine
Sponsor Name
